Atai Beckley N.V. (ATAI)
NASDAQ:ATAI
Want to see ATAI full AI Analyst Report?
Top Page
Atai Beckley N.V.
(NASDAQ:ATAI)
Select Model
Select Model
Rating:50Neutral
Price Target:
$5.00
▲(24.07% Upside)
Action:ReiteratedDate:04/21/26
Overall score is held back primarily by weak financial performance (large losses and ongoing cash burn despite only modest revenue) and an unattractive profitability-linked valuation (negative P/E). Technicals are a partial offset, with strong upward momentum and price above major moving averages, though overbought RSI reduces confidence.
Positive Factors
Platform partnerships and licensing
Atai's platform model creates multiple non-dilutive and contingent funding pathways (upfronts, milestones, royalties, program exits). Structurally this provides diversified shots on goal and potential downstream revenue streams that can support R&D spend without sole reliance on product sales.
Negative Factors
Persistent cash burn
Consistent negative operating cash flow and large negative free cash flow create structural funding needs. Over the medium term the company will require frequent financing or milestone monetization, increasing dilution risk and constraining ability to advance multiple programs simultaneously.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform partnerships and licensing
Atai's platform model creates multiple non-dilutive and contingent funding pathways (upfronts, milestones, royalties, program exits). Structurally this provides diversified shots on goal and potential downstream revenue streams that can support R&D spend without sole reliance on product sales.
Read all positive factors
Atai Beckley N.V. (ATAI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.46B
Dividend YieldN/A
Average Volume (3M)4.81M
Price to Earnings (P/E)―
Beta (1Y)1.40
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees54
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)N/A
Shares Outstanding364,745,970
10 Day Avg. Volume4,706,750
30 Day Avg. Volume4,811,811
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)4.18
Price to Sales (P/S)226.59
P/FCF Ratio-8.95
Enterprise Value/Market Cap0.58
Enterprise Value/Revenue205.22
Enterprise Value/Gross Profit-124.34
Enterprise Value/Ebitda-7.42
Forecast
1Y Price Target
$14.80Price Target Upside267.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.48
Revenue Forecast (FY)$430.77K
Atai Beckley N.V. Business Overview & Revenue Model
Company Description
Atai Beckley NV is a clinical-stage biopharmaceutical company. It engages in the treatment of mental health disorders. The company was founded by Christian Angermayer, Florian Brand, Srinivas Rao and Lars Christian Wilde in June 2018 and is headqu...
How the Company Makes Money
ATAI is a clinical-stage company and, as such, it does not primarily generate recurring revenue from commercialized products. Its potential and historical sources of cash inflow are typically tied to its drug-development platform: (1) partnering a...
Atai Beckley N.V. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
28
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.09M | 308.00K | 314.00K | 233.00K | 20.38M |
| Gross Profit | 3.08M | 308.00K | 314.00K | 233.00K | 20.38M |
| EBITDA | -113.05M | -144.81M | -36.31M | -134.09M | -120.28M |
| Net Income | -660.05M | -149.27M | -40.22M | -152.38M | -167.81M |
Balance Sheet | |||||
| Total Assets | 310.54M | 159.39M | 293.48M | 305.44M | 414.17M |
| Cash, Cash Equivalents and Short-Term Investments | 256.04M | 62.33M | 179.26M | 273.11M | 362.27M |
| Total Debt | 2.07M | 24.71M | 19.14M | 15.34M | 743.00K |
| Total Liabilities | 88.54M | 42.83M | 49.16M | 39.67M | 28.21M |
| Stockholders Equity | 221.87M | 116.30M | 242.96M | 260.74M | 376.91M |
Cash Flow | |||||
| Free Cash Flow | -103.58M | -82.53M | -84.71M | -105.49M | -64.37M |
| Operating Cash Flow | -102.67M | -82.44M | -84.12M | -104.47M | -63.25M |
| Investing Cash Flow | -109.13M | 59.17M | -53.30M | -86.85M | -81.28M |
| Financing Cash Flow | 269.48M | 5.37M | -8.36M | 20.79M | 409.86M |
Atai Beckley N.V. Technical Analysis
Positive
4.03
Price Trends
3.74
Positive
3.86
Positive
4.17
Negative
Market Momentum
0.08
Negative
60.40
Neutral
70.20
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATAI, the sentiment is Positive. The current price of 4.03 is above the 20-day moving average (MA) of 3.68, above the 50-day MA of 3.74, and below the 200-day MA of 4.17, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 60.40 is Neutral, neither overbought nor oversold. The STOCH value of 70.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATAI.
Atai Beckley N.V. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $2.39B | -5.95 | -399.10% | ― | -32.79% | 36.87% | |
60 Neutral | $9.47B | -21.87 | -58.74% | ― | 364.98% | -25.33% | |
52 Neutral | $1.03B | -5.55 | -38.79% | ― | ― | 4.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $1.46B | -0.59 | -389.74% | ― | ― | ― | |
49 Neutral | $1.43B | -14.03 | -84.99% | ― | 103.75% | 33.84% |
* Healthcare Sector Average
ATAI
Atai Beckley N.V.
4.90
3.48
245.07%
NKTR
Nektar Therapeutics
100.35
90.96
968.92%
WVE
Wave Life Sciences
7.58
1.46
23.86%
ORIC
Oric Pharmaceuticals
10.89
6.02
123.61%
PRAX
Praxis Precision Medicines
342.57
307.23
869.35%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.